Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

• Váldodahkkit: Ying Hong (Dahkki), Tomoko Ishizuka (Dahkki), Akiko Watanabe (Dahkki), Masaya Tachibana (Dahkki), Mark Lee (Dahkki), Hitoshi Ishizuka (Dahkki), Frank LaCreta (Dahkki), Malaz Abutarif (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Milademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. Milademetan is a CYP3A and P‐glycoprotein substrate and moderate CYP3A inhibitor....